RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma
The first patients have been screened and a first patient has been dosed in the open-label, dose escalation Phase Ib/II study with YELIVA® (ABC294640) for multiple myeloma
The Phase Ib/II clinical study is intended to evaluate the safety and efficacy of YELIVA® in up to 77 patients with refractory or relapsed multiple myeloma who have previously been treated with proteasome inhibitors and immunomodulatory drugs
The study is supported by a $2 million grant from the National Cancer Institute (NCI) awarded to Apogee Biotechnology Corp., with additional support from RedHill
YELIVA® is a proprietary, first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor, with anti-cancer and anti-inflammatory activities; RedHill is pursuing several Phase I/II and Phase II clinical studies with YELIVA® in the U.S., targeting multiple oncology and inflammatory indications
- Worldwide sales of multiple myeloma therapies are estimated to exceed $12 billion in 2016
TEL-AVIV, Israel, Dec. 19, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that the first patients have been screened and a first patient has been dosed in the Phase Ib/II clinical study evaluating YELIVA® (ABC294640) in patients with refractory or relapsed multiple myeloma.
The open-label, dose escalation Phase Ib/II study is being conducted at Duke University Medical Center and is expected to enroll up to 77 patients with refractory or relapsed multiple myeloma who have previously been treated with proteasome inhibitors and immunomodulatory drugs.
Dr. Yubin Kang, MD, Associate Professor in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at Duke University School of Medicine, is the lead investigator for the study.
The study is supported by a $2 million grant from the National Cancer Institute (NCI) Small Business Innovation Research Program (SBIR) awarded to Apogee Biotechnology Corp. (Apogee), in conjunction with Duke University, with additional support from RedHill.
YELIVA® is a proprietary, first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor, with anti-cancer and anti-inflammatory activities. By inhibiting the SK2 enzyme, YELIVA® blocks the synthesis of sphingosine 1-phosphate (S1P), a lipid signaling molecule that promotes cancer growth and pathological inflammation.
RedHill is pursuing and evaluating multiple clinical programs in oncology, inflammatory and gastrointestinal indications with YELIVA®, as well as potential collaboration opportunities with larger pharmaceutical companies to evaluate YELIVA® as an add-on therapy to existing oncology treatments.
Results from a Phase I study with YELIVA® in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina Hollings Cancer Center (MUSC), successfully met its primary and secondary endpoints, demonstrating that the drug is well-tolerated and can be safely administered to cancer patients at doses that provide circulating drug levels that are predicted to have therapeutic activity.
A Phase II study with YELIVA® for the treatment of advanced hepatocellular carcinoma (HCC) was initiated at MUSC Hollings Cancer Center, following ethics approval and successful submission to the U.S. FDA. The study is supported by a $1.8 million grant from the NCI, awarded to MUSC, which is intended to fund a broad range of studies on the feasibility of targeting sphingolipid metabolism for the treatment of a variety of solid tumor cancers, with additional support from RedHill.
A Phase I/II clinical study evaluating YELIVA® in patients with refractory/relapsed diffuse large B-cell lymphoma was initiated at the Louisiana State University Health Sciences Center in New Orleans in June 2015 and was recently amended to address overall recruitment prospects. The study will now also include Kaposi sarcoma patients. The study is supported by a grant from the NCI awarded to Apogee, with additional support from RedHill.
A Phase Ib study to evaluate YELIVA® as a radioprotectant for prevention of mucositis in head and neck cancer patients undergoing therapeutic radiotherapy is planned to be initiated in the first half of 2017.
Additional Phase I/II studies with YELIVA® for other indications are in various stages of preparation.
The ongoing studies with YELIVA® (ABC294640) are registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.
About Multiple Myeloma:
Multiple myeloma is a malignant plasma cell disorder which is usually not curable1. Symptomatic multiple myeloma is characterized by a clonal proliferation of plasma cells preceding clinical findings that include bone lesions, fractures, anemia, renal failure and hypercalcemia2. Approximately 30,000 new cases of multiple myeloma are expected to be diagnosed in the U.S. in 2016, accounting for 1.8% of all cancers. The 5-year survival rate of myeloma is estimated at 48.5% and approximately 95,000 people are living with myeloma in the United States3. The risk of multiple myeloma increases as people age. Most patients diagnosed with this cancer are at least 65 years old4, making treatment with the most effective therapies problematic. The worldwide sales of multiple myeloma therapies are estimated to exceed $12 billion in 20165.
About YELIVA® (ABC294640):
YELIVA® (ABC294640) is a Phase II-stage, proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with anti-cancer and anti-inflammatory activities. RedHill is pursuing with YELIVA® multiple clinical programs in oncology, inflammatory and gastrointestinal indications. By inhibiting the SK2 enzyme, YELIVA® blocks the synthesis of sphingosine 1-phosphate (S1P), a lipid signaling molecule that promotes cancer growth and pathological inflammation. SK2 is an innovative molecular target for anticancer therapy because of its critical role in catalyzing the formation of S1P, which is known to regulate cell proliferation and activation of inflammatory pathways. YELIVA® was originally developed by U.S.-based Apogee Biotechnology Corp. and completed multiple successful pre-clinical studies in oncology, inflammation, GI and radioprotection models, as well as the ABC-101 Phase I clinical study in cancer patients with advanced solid tumors. The Phase I study included the first-ever longitudinal analysis of plasma S1P levels as a potential pharmacodynamic (PD) biomarker for activity of a sphingolipid-targeted drug. The administration of YELIVA® resulted in a rapid and pronounced decrease in S1P levels, with several patients having prolonged stabilization of disease. The development of YELIVA® was funded to date primarily by grants and contracts from U.S. federal and state government agencies awarded to Apogee Biotechnology Corp., including the U.S. National Cancer Institute, the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), the U.S. Department of Defense and the FDA Office of Orphan Products Development.
About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) is a biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill’s pipeline of proprietary products includes: (i) RHB-105 - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study; (ii) RHB-104 - an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study and a completed proof-of-concept Phase IIa study for multiple sclerosis; (iii) BEKINDA® (RHB-102) - a once-daily oral pill formulation of ondansetron with an ongoing Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered uPA inhibitor, targeting gastrointestinal and other solid tumors and (vii) RIZAPORT® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in Germany in October 2015.
1 Ludwig, H., et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 28, 1599-1605 (2010).
2 Kyle, R.A. & Rajkumar, S.V. Multiple myeloma. Blood 111, 2962-2972 (2008).
3 ‘Surveillance, Epidemiology, and End Results Program’, Myeloma
4 American Cancer Society, Multiple Myeloma (January 2016)
5 GlobalData Pharma eTrack, multiple myeloma estimated market size (September 2016)
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to establish and maintain corporate collaborations; (vi) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (vii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (viii) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (ix) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (x) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xi) estimates of the Company’s expenses, future revenues capital requirements and the Company’s needs for additional financing; (xii) competitive companies and technologies within the Company’s industry; and (xiii) the impact of the political and security situation in Israel on the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 25, 2016. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.
Senior VP Business Development & Licensing
IR contact (U.S.):
Senior Vice President
The Trout Group
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Tenaris Announces 2017 Fourth Quarter and Annual Results21.2.2018 23:49 | Pressemelding
Tenaris S.A. / Tenaris Announces 2017 Fourth Quarter and Annual Results . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. The financial and operational information contained in this press release is based on audited consolidated financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Net cash / debt and Free Cash Flow. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE:TS) (BAE:TS) (BMV:TS) (MILAN:TEN) ("Tenaris") today announced its results for the fourth quarter and year ended December 31, 2017 with comparison to its results for the fourth quarter and year e
InnovMetric Acquires Prefixa Vision Systems21.2.2018 21:22 | Pressemelding
Consolidates its market presence in Mexico QUEBEC CITY, Feb. 21, 2018 (GLOBE NEWSWIRE) -- InnovMetric Software Inc., the leading provider of universal 3D metrology software solutions, today announced the acquisition of Prefixa Vision Systems, its PolyWorks® Master distributor in Mexico, following five years of successful cooperation. "The growth of the automotive industry in Mexico has been so phenomenal in recent years that in our latest fiscal year Mexico became the 5th largest PolyWorks market in the world. InnovMetric is deeply committed to expanding its local technical expertise to assist its Mexican customers in their successful migration to the PolyWorks universal 3D metrology software platform," said Marc Soucy, President of InnovMetric. The acquisition allows InnovMetric to expand the capabilities of its local subsidiary, PolyWorks Mexico, which include supporting and training Mexican customers and assisting local metrology hardware partners. PolyWorks Mexico will also market
Taconic Biosciences Announces the Formation of Scientific Advisory Board21.2.2018 19:13 | Pressemelding
RENSSELAER, N.Y., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced the formation of its Scientific Advisory Board (SAB) with the initial appointments of J. Victor Garcia, PhD, Andrew Goodman, PhD, and David Hill, PhD. The SAB will collaborate with Taconic's management in providing scientific insight and guidance on the evolution of the company's product and service portfolios. Capitalizing on Taconic's existing leadership in both the microbiome and immuno-oncology spaces, the SAB members bring complementary expertise to continue to drive innovation in these and other research areas. "Discovery and pre-clinical animal models continue to move toward highly-complex and high-value translational models. To continue to provide the best solutions for our customers, it is essential for Taconic to have guidance from prominent scientific experts as we develop and validate new models and services," sha
SD-WAN Market Leader Aryaka Further Expands UK and EMEA Market Reach with Intergence Partnership21.2.2018 16:01 | Pressemelding
Partnership Enables More UK and EMEA Enterprises to Adopt Global SD-WAN as-a-Service LONDON, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Aryaka®, the leading global SD-WAN provider, today announced that Cambridge, UK-based Intergence will deploy Aryaka's global SD-WAN solution to enhance global connectivity and application performance for its enterprise customers with offices in the UK and Europe. Partnering with Aryaka strengthens Intergence's infrastructure services proposition for its global enterprise customers. Intergence comprises a team of IT infrastructure experts that help organizations realize their digital transformation objectives. Formed in 2003, the company uses innovative technologies like its Stratiam(TM) solution to provide CIOs with insights about IT performance and the customer's digital experiences, and to simplify complex IT problems. Intergence's infrastructure services provide IT leaders with greater flexibility, agility, and cost efficiency. The partnership will enable In
TrueCommerce Dynamics 365 Solution Featured on Microsoft AppSource21.2.2018 16:00 | Pressemelding
TrueCommerce Solution Delivers Powerful Supply Chain Integration Capabilities to Dynamics 365 Community PITTSBURGH, Feb. 21, 2018 (GLOBE NEWSWIRE) -- TrueCommerce, a global provider of trading partner connectivity and integration solutions, has announced today that its Microsoft Dynamics 365 solution is available on Microsoft AppSource. Built exclusively for and within the native Dynamics 365 platform, the embedded solution connects directly with TrueCommerce's global commerce network, offering immediate access to more than 92,000 pre-connected retailers, marketplaces, distributors, vendors and logistics providers. "Our solution for Dynamics 365 offers a multi-company, multi-deployment architecture that scales to support complex enterprise requirements," said TrueCommerce president Ross Elliott. "We are excited to be selected as one of the few EDI solutions to be featured on Microsoft AppSource, recognition of having achieved Microsoft's highest standards for quality and reliability fo
Colliers International Named to IAOP® Global Outsourcing 100 List for 13th Consecutive Year21.2.2018 15:00 | Pressemelding
International Association of Outsourcing Professionals® Honors Colliers in Its Annual Listing of the World's Best Outsourcing Service Providers TORONTO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) is pleased to announce that it has again been selected for The 2018 Global Outsourcing 100 list by IAOP®, an honor the company has earned for 13 straight years, more than any other real estate services provider. Colliers has been named to the list each year since its inception. Colliers is committed to leadership in the global outsourcing industry and has a proven track-record in the space. The company's outstanding growth continues through a focus on maintaining the most collaborative and creative culture in the industry, allowing clients to accelerate their success by sharing its market-leading expertise. "We are honored to again receive this prestigious recognition from IAOP," said Dylan Ta
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom